Endo Inc.

OTCPK:NDOI Stock Report

Market Cap: US$1.9b

Endo Valuation

Is NDOI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NDOI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NDOI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NDOI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NDOI?

Key metric: As NDOI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NDOI. This is calculated by dividing NDOI's market cap by their current earnings.
What is NDOI's PE Ratio?
PE Ratio0.6x
EarningsUS$3.37b
Market CapUS$1.91b

Price to Earnings Ratio vs Peers

How does NDOI's PE Ratio compare to its peers?

The above table shows the PE ratio for NDOI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28x
LGND Ligand Pharmaceuticals
46.6x35.5%US$2.1b
SUPN Supernus Pharmaceuticals
33.4x36.2%US$2.0b
INVA Innoviva
18.6xn/aUS$1.2b
AMPH Amphastar Pharmaceuticals
13.4x13.6%US$2.1b
NDOI Endo
0.6xn/aUS$1.9b

Price-To-Earnings vs Peers: NDOI is good value based on its Price-To-Earnings Ratio (0.6x) compared to the peer average (27.8x).

Price to Earnings Ratio vs Industry

How does NDOI's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

12 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.20.1x23.8%
NDOI Endo
 0.6xn/aUS$1.91b
OGN Organon
2.9x-7.1%US$3.76b
PROC Procaps Group
1.2xn/aUS$59.68m
NDOI 0.6xIndustry Avg. 20.1xNo. of Companies12PE01224364860+
12 CompaniesEstimated GrowthMarket Cap
Industry Avg.20.1x23.8%
NDOI Endo
 0.6xn/aUS$1.91b
No more companies

Price-To-Earnings vs Industry: NDOI is good value based on its Price-To-Earnings Ratio (0.6x) compared to the US Pharmaceuticals industry average (19.9x).

Price to Earnings Ratio vs Fair Ratio

What is NDOI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NDOI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio0.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NDOI's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%